Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: assessment of therapy complications; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years
Enrollment: 3,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 451
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more

Conditions: Prostate Cancer, Prostatectomy, Erectile Dysfunction Following Radical Prostatectomy, Incontinence, Urinary
Interventions: BioDFence G3; Biological
Lead sponsor: AdventHealth; Other
Eligibility: 40 Years to 70 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Celebration, Florida

Conditions: Adenocarcinoma, Prostate Neoplasms, Prostate Cancer, Renal Cell Carcinoma, Von Hippel Lindau Disease
Interventions: EM Tracking; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 3,894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Interventions: Olaparib, LHRH agonist; Drug
Lead sponsor: Rana McKay, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: La Jolla, California • Baltimore, Maryland • New York, New York + 2 more

Conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions: Not listed
Lead sponsor: Viatar LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lawrence, Massachusetts

Conditions: Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions: Cancer Therapeutic Procedure, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Interventions: NUV-1511; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Detroit, Michigan • Hackensack, New Jersey • New York, New York + 5 more

Conditions: Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Neoplasms, Uterine Cervical Neoplasms, Leukemia, Lymphoma, Non-Hodgkin
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 992 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Doxorubicin Hydrochloride, Estramustine phosphate sodium, Etoposide, Ketoconazole, Paclitaxel, Vinblastine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Localized Prostate Carcinoma, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions: Apalutamide, Biospecimen Collection, Quality-of-Life Assessment; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 2 more

Conditions: Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Microsatellite Instability
Interventions: Durvalumab, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Lymphoma, Neoplasm, Prostatic Neoplasm
Interventions: 7-hydroxystaurosporine (UCN-01); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Lesions
Interventions: magnetic resonance imaging; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 21 Years to 80 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Irvine, California

Conditions: Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Cancer, Prostate Cancer, Lung Cancer
Interventions: Educational materials, educational materials, plus patient navigation; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Brain Tumors, Gastric Cancer, Ovarian Cancer, Prostate Cancer
Interventions: KLH, GMCSF; Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 13
States / cities: Bay City, Michigan • Port Huron, Michigan • Bellingham, Washington + 6 more

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b, Rintatolimod; Drug · Procedure · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer
Interventions: selenium, placebo; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer Early Risk Treated by Radiosurgery, Prostate Cancer Intermediate Risk Treated by Radiosurgery
Interventions: Not listed
Lead sponsor: RPCR, Inc.; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 44
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 39 more

Conditions: Prostate Cancer
Interventions: Blood draw; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Motor Function, Cognitive Function, Contrast Media
Interventions: Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol; Procedure · Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 16
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more

Conditions: Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
Interventions: SRS/SBRT; Radiation
Lead sponsor: The Radiosurgery Society; Other
Eligibility: Not listed
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 13
States / cities: Colorado Springs, Colorado • Miami, Florida • Brunswick, Georgia + 10 more

Conditions: Prostate Cancer
Interventions: Custirsen, Docetaxel, Prednisone, Dexamethasone; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Marina del Rey, California + 20 more

Conditions: Prostate Cancer
Interventions: Histolog Scan; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy

Use of Tracking Devices to Locate Abnormalities During Invasive Procedures

CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Collection of Blood Specimens for Circulating Tumor Cell Analysis

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Imaging of Prostate Cancer Using Two-dimensional MR Spectroscopy and Diffusion Tensor Imaging

Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial

S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer

Multi-Institutional Registry for Prostate Cancer Radiosurgery

A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen